NCT04443322View on ClinicalTrials.gov

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 19, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2025

Conditions
Liver CarcinomaLiver Transplant; Complications
Interventions
DRUG

Durvalumab Injection

Anti-PD-L1 Monoclonal Antibody

DRUG

Lenvatinib 4 MG

Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.

Trial Locations (1)

200127

RECRUITING

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER